NCT06147362View on ClinicalTrials.gov

68Ga-NOTA-PEG2-RM26 PET/CT, First in Man Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Cancer
Interventions
DRUG

68Ga-NOTA-PEG2-RM26

Single-dose 68Ga-NOTA-PEG2-RM26, a gastrin-releasing peptide receptor antagonist linked with a positron emitting radioisotope intravenously injected into participants before the PET/CT scans.

Trial Locations (1)

17176

RECRUITING

Karolinska University Hospital, Stockholm

All Listed Sponsors
collaborator

Stockholm South General Hospital

OTHER

collaborator

Uppsala University

OTHER

lead

Karolinska University Hospital

OTHER